Orsenix Eyes Opportunity For Oral Arsenic Leukemia Therapy
Teva's Trisenox, an IV formulation of arsenic trioxide, was recently approved by the FDA as a first-line treatment for acute promyelocytic leukemia but Incyte founder Kris Vaddi's Orsenix believes its Phase III-ready oral version will take over the market.
You may also be interested in...
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.